Allogeneic hematopoietic stem cell transplantation (SCT) from unaffected donors remains the only modality for the correction of hematological abnormalities in Fanconi anemia (FA) patients. We performed four HLA-matched related donor SCT using a novel irradiation and cyclophosphamide-free conditioning regimen. The protocol included fludarabine 150 mg/m 2 , busulfan 4 mg/kg, and antithymocyte globulin 90 mg/kg. Graft-versus-host disease (GVHD) prophylaxis was cyclosporin A, MTX, and daclizumab. The engraftment and occurrence of full stable donor hemopoiesis was rapid in all cases with minimal short-term toxic complications. There were no infections or febrile episodes during the inpatient phase. Three patients developed acute GVHD grade I-II involving gut and skin and one patient progressed to extensive chronic GVHD. The preparative conditioning regimen is safe and associated with low organ toxicity and effective immunosupression for the stable engraftment in FA patients undergoing SCT with matched related donors. 1 FA cells are characterized by chromosomal instability and marked DNA hypersensitivity to crosslinking alkylating agents such as cyclophosphamide or platinum derivatives. 2, 3 This hypersensitivity forms the basis for the confirmatory tests for FA with diepoxybutane (DEB), nitrogen-mustard, and others. Bone marrow failure remains the main cause of mortality among the FA patients, followed by complications of stem cell transplantation (SCT) and myeloid and nonmyeloid malignancies. Allogeneic hematopoietic SCT from unaffected sibling donors or suitably matched unrelated donors remains the only curative option for the correction of hematological abnormalities in FA patients. In the past, the use of highdose cyclophosphamide and ionizing radiation in preparative regimens often resulted in excessive organ toxicity and death in the early post transplant period. Low-doses of cyclophosphamide (20-40 mg/kg) combined with a 4-6 Gy of thoraco-abdominal or total body irradiation results in reduced toxicity and substantially improves the outcome for the FA patients transplanted from HLA-matched donors. 4 However, reduced doses of cyclophosphamide may not kill DEB-resistant naturally reverted T-lymphocytes, thereby increasing the risk of rejection in mosaic recipients of unrelated grafts (J Wagner, unpublished). Moreover, longterm follow-up clearly shows that these protocols are still associated with significant regimen-related toxicity and high risk of secondary malignant transformations.
sibling donor; fludarabine; busulfan Fanconi anemia (FA) is a rare autosomal recessive syndrome of progressive marrow failure, constitutional physical abnormalities of skin, skeleton, kidneys, and cancer susceptibility. 1 FA cells are characterized by chromosomal instability and marked DNA hypersensitivity to crosslinking alkylating agents such as cyclophosphamide or platinum derivatives. 2, 3 This hypersensitivity forms the basis for the confirmatory tests for FA with diepoxybutane (DEB), nitrogen-mustard, and others. Bone marrow failure remains the main cause of mortality among the FA patients, followed by complications of stem cell transplantation (SCT) and myeloid and nonmyeloid malignancies. Allogeneic hematopoietic SCT from unaffected sibling donors or suitably matched unrelated donors remains the only curative option for the correction of hematological abnormalities in FA patients. In the past, the use of highdose cyclophosphamide and ionizing radiation in preparative regimens often resulted in excessive organ toxicity and death in the early post transplant period. Low-doses of cyclophosphamide (20-40 mg/kg) combined with a 4-6 Gy of thoraco-abdominal or total body irradiation results in reduced toxicity and substantially improves the outcome for the FA patients transplanted from HLA-matched donors. 4 However, reduced doses of cyclophosphamide may not kill DEB-resistant naturally reverted T-lymphocytes, thereby increasing the risk of rejection in mosaic recipients of unrelated grafts (J Wagner, unpublished). Moreover, longterm follow-up clearly shows that these protocols are still associated with significant regimen-related toxicity and high risk of secondary malignant transformations. 5 More specifically, high incidence and severity of acute and chronic graft-versus-host disease (GVHD) in FA patients, who received cyclosporine alone as the GVHD prophylaxis, significantly contributed to transplantation-related morbidity and mortality, in addition favoring development of late epithelial cancers in irradiated patients. These observations prompted a search for less toxic regimens for FA patients undergoing SCT. Combinations of fludarabine and lowdose cyclophosphamide or fludarabine plus minimal-dose (2 Gy) TBI are most extensively explored. [6] [7] [8] [9] With the aim of further reduction of regimen-related toxicity and GVHD rates, we tested a novel SCT conditioning protocol with fludarabine, low-dose busulfan, and antithymocyte globulin. The use of cyclophosphamide and gamma-irradiation has been omitted. GVHD prophylaxis was reinforced by addition of 'mini'-methotrexate and daclizumab. This conditioning regimen showed low toxicity with sufficient immunosuppression that allowed prompt engraftment of HLA-matched sibling donor transplants.
Patients and results
Four patients have been treated according to proposed protocol. All SCT were performed from HLA-identical sibling donors. Three patients were grafted with bone marrow and one with bone marrow combined with the thawed umbilical cord blood unit from the HLA-matched sister. All donors were tested for chromosomal instability with a DEB-test before donation and proved to be unaffected.
At the time of SCT, female patient UPN86 was 7 years old. She was diagnosed with FA by positive DEB test 1 year before and belonged to the FAA complementation group. She exhibited minor physical abnormalities such as short stature and spotty skin depigmentation. She failed to improve on metandrostenolone and was maintained on RBC and platelet transfusions. She developed refractoriness to platelets.
The male patient UPN100 was diagnosed with progressive three-lineage bone marrow aplasia at the age of 7 years. Diagnosis of FA was confirmed by positive DEB-test; the complementation analysis showed FA group A. The boy has typical FA features: short stature, bird face and 'cafe´-au-lait' spots. He had minimal response to therapy with prednisolone and metandrostenolone and required multiple blood transfusions. At the time of SCT he developed platelet transfusion refractoriness due to anti-HLA antibodies.
Female patient UPN127 was diagnosed with aplastic anemia at age of 5 years. After developing severe anemia and thrombocytopenia, she was finally diagnosed with FA by DEB testing. The girl has a number of physical abnormalities including multiple areas of skin hyperpigmentation, growth retardation, abnormal thumbs, and kidney defects. She was treated with steroids with partial hematological response, but later transfusion dependency developed.
The fourth patient UPN155 was diagnosed with FA at the age of 6 years. The clinical features were mild anemia and thrombocytopenia. She was not transfusion dependent and did not receive any FA-directed treatment.
All patients were nursed in single laminar airflow rooms. Antimicrobial prophylaxis consisted of amoxicillin, ciprofloxacin, fluconazole, and tromethoprim. Acyclovir 250 mg/ m 2 t.i.d. was given i.v. from day þ 1 to day 21, and then continued orally at least 6 months.
The conditioning regimen consisted of fludarabine 150 mg/m 2 (30 mg/m 2 /day intravenously from day À6 to day À2), busulfan (Myleran, Glaxo-Wellcome) 1 mg/kg (orally every 12 h, days À6 and À5, total dose 4 mg/kg), and horse antithymocyte globulin (ATGAM, PharmaciaUpjohn, Kalamazoo, USA) 30 mg/kg/day from day À3 to day À1. 8 cells/kg). All patients were CMV positive according to serological evaluation. CMV-viremia was monitored weekly by a qualitative PCR. Hematopoietic chimerism was assessed once upon engraftment by a standard cytogenetics test for sex-mismatched patient/donor pairs and using short tandem repeat (STR) polymorphism in sexmatched pairs.
Results
All patients showed rapid stem cell engraftment and achieved a neutrophil count 40.5 Â 10 9 /l on day 14 for UPN86 and UPN155; days 17 and 12 post transplantation for UPN100 and UPN127, respectively. An unsupported platelet count 450 Â 10 9 /l was achieved on day þ 15 for patients UPN 86 and UPN127; days þ 19 and þ 17 for UPN100 and UPN155, respectively (Table 1) . Full stable donor hemopoiesis was confirmed in all the patients. There were no febrile episodes among the patients in the neutropenic phase of post transplantation follow-up. The transplant-related toxicity was very mild in all patients. Three of them experienced grade I mucositis and one (UPN86) grade II mucositis. This patient required morphine treatment and total parenteral nutrition. No other visceral toxicity such as cystitis, vomiting, or diarrhea was recorded during the first 100 days after transplant.
Two patients UPN86 and UPN127 developed grade I gut and one (UPN155) developed grade II aGVHD involving skin and gut. In all patients, aGVHD was successfully treated with conventional doses of glucocorticoids. In UPN155, CsA was inadvertently interrupted by parents 5 months after SCT, resulting in development of extensive chronic GVHD of the lung. Interstitial pneumonia and broncho-obstructive obliterating pulmonitis (BOOP) were diagnosed and treated with prednisolone, mycophenolate, and infliximab with transitory response.
All patients were discharged from the hospital at the median of day þ 35 post SCT. There was one readmission (UPN155) due to chronic GVHD and BOOP formation.
As of December 2003, three patients (UPN86, UPN100, and UPN127) were alive and well with the follow-up period 
Discussion
Allogeneic stem cell transplantation remains the only option able to restore permanently hemopoietic function in FA patients. While reduction of cyclophosphamide and irradiation dose in the pre-transplant conditioning regimen has led to significant decrease in morbidity and mortality among FA patients undergoing SCT, there is still considerable room for improvement of the toxicity profile of conditioning. Furthermore, use of preparative regimens with bifunctional alkylating agents and irradiation even in low dose may increase the risk of secondary malignant transformation in the latter course of these patients.
5
'Non-irradiation' regimens for FA, based on fludarabine and cyclophosphamide, show sustained engraftment and look promising in the terms of toxicity profile. 10, 11 An optimal preparative regimen for SCT in FA must aim to ensure durable engraftment, low incidence of GVHD and organ toxicity rate, and avoid cancer risk factors. The wellknown association between the use of low-dose bifunctional alkylating agents and organ toxicity, GVHD development and late malignant transformation in patients at increased inherent risk for it, 12 led us to look for another effective way to produce adequate immunosupression in the settings of SCT for FA patients.
We designed a novel irradiation and cyclophosphamidefree preparative regimen. Our protocol enables rapid and stable engraftment in all patients, even in one who received a low dose of nucleated cells (UPN100 -umbilical cord blood and bone marrow). Neither previous treatment with androgens nor HLA-alloimmunization, due to multiple transfusions known to enhance risk of graft failure, 13, 14 compromised engraftment in our series. The minimal toxicity associated with this protocol makes it suitable for pediatric FA patients even in poor clinical condition before SCT. The combined immunosuppression prevented the occurrence of high-grade aGVHD, known to be a significant problem in FA patients receiving CsA alone post transplant, although the exact role of daclizumab is still obscure. Acute GVHD were seen in three patients, but only one patient developed aGVHD4grade I. All the patients were successfully treated with first-line therapy.
In summary, we report the possibility of using a nonirradiation, noncyclophosphamide-conditioning regimen for FA patients with HLA-matched related donors. This protocol enables rapid engraftment in FA patients undergoing SCT and is associated with low shortterm organ toxicity.
Avoiding the use of bifunctional alkylating agents may reduce the long-term risk of secondary malignancies. Longer follow-up and more patients are necessary to determine whether the described regimen is appropriate for ensuring engraftment and low GVHD rate in all complementation groups of FA.
